Trial Profile
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 25 Apr 2024
Price :
$35
*
At a glance
- Drugs BMS 986218 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 25 Apr 2024 This trial has been completed in Germany (Global end date: 4 Apr 2024).
- 24 Apr 2024 This trial has been completed in Netharlands, according to European Clinical Trials Database record.
- 21 Mar 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.